Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

NCT06734130 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Castration Sensitive Prostate Cancer

Interventions

DRUG: Luteinizing Hormone-Releasing Hormone (LHRH) analog
DRUG: Androgen Receptor Signal Inhibitor (ARSI)
DRUG: Docetaxel

Sponsor

H. Lee Moffitt Cancer Center and Research Institute